Pharmacogenetic Data Will Have “Safe Harbor,” CDER’s Galson Says
Executive Summary
FDA is encouraging companies to submit pharmacogenetic data to the agency under the assurance that data suggesting risk of a product will not impact regulatory decisions, Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, said May 16
You may also be interested in...
FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group
FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group
Pharmacogenetic Drug Trials: Genetic Test Availability Will Determine Scope
Drugs that are more effective in populations defined through pharmacogenetic studies may need testing in broader populations as well, depending on whether screening is available to identify the appropriate patients in clinical practice, FDA Medical Policy Director Robert Temple, MD, said